Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

With SYNGENE's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 0.000000
forwardPE 39.107426
debtToEquity 14.488000
earningsGrowth 0.177000
revenueGrowth 0.106000
grossMargins 0.684100
operatingMargins 0.183530
trailingEps 12.510000
forwardEps 16.850000

SYNGENE's low Debt-to-Equity ratio suggests the company is minimally leveraged, with limited reliance on debt to finance its operations. This reduced financial risk positions the company for greater stability and financial health, appealing to investors who value conservative financial management.
Positive earnings and revenue growth for Syngene International Limited suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
With a forward EPS greater than its trailing EPS, SYNGENE is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

Price projections for SYNGENE have gradually risen over time, signaling increased optimism about the company's future prospects. This steady upward revision reflects growing confidence in SYNGENE's market potential.

Insider Transactions:

Insider Transactions for SYNGENE
Insider Transactions for SYNGENE


36 transactions to sell SYNGENE occurred, with market price at 790.8194410536024.No sell transactions were completed during the period under review.The recent trend of increased buying at SYNGENE's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


The recent buy bias from analysts suggests SYNGENE is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, SYNGENE appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.